

References

I-216

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Health and Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid>
2. Selling ASK, Harslof T, Langdahl B. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. *Ther Adv Musculoskel Dis*. 2018;10(56):105-115.
3. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int*. 2022;33(10):2049-2102.
4. Barrioneuvo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. *J Clin Endocrinol Metab*. 2019;104(5):1623-1630.
5. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. *J Clin Endocrinol Metab*. 2020;105(3):587-594.
6. Jeremiah MP, Unwin BK, Greenawald MH, et al. Diagnosis and management of osteoporosis. *Am Fam Physician*. 2015;92(4):261-268.
7. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al: Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2017;35(18):2062-2081.
8. Evenity (romosozumab) injection, for subcutaneous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 04/2020.
9. Clinical Pharmacology TM 2022. Tampa FL: Gold Standard, Inc. Romosozumab.
10. Micromedex DrugDex Compendium®. 2022.
11. Romosozumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated June 8, 2020.